undamentalytics Newsletter
Sign in

Beam Therapeutics Inc. (BEAM) stock

Add to watchlist

Add holding +

NASDAQ: BEAM Nasdaq Biotechnology Next results ~November 3, 2026

C+ Fundamentals grade

Beam Therapeutics Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$8.1

Growth cash-flow model

Base case. Range ~$7.8–$8.3. Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Beam Therapeutics Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 7 selling0 purchases and 31 sales by directors and officers, last 12 monthsInsider trades
  • Funds148 adding, 106 cuttingOf 42 active managers that changed their stake, 28 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Beam Therapeutics files

Where Beam Therapeutics stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $156m, up 158.9% on a year earlier, faster than the 158.0% growth a quarter earlier. That growth ranks 5 of 49 among the biotechnology companies we cover. Free-cash-flow margin rose to -238.9% from -589.9% a year earlier. Operating margin widened to -242.3% from -739.9%. The diluted share count is up 16.3% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 5 of our 6 financial-health checks.

Source: 10-Q filed August 4, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 3, 2026 (estimated)

Beam Therapeutics Inc.'s trailing-twelve-month revenue grew 163.3% year on year, with a free-cash-flow margin of -271.6%. Where it stands out: revenue growth of 163.3% ranks 28 of 172 biotechnology companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 13.0% while net income grew 73.8%: a 87pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 163.3% over the last 12 months, against a median of 12.8% for biotechnology companies we cover.
  • Growth speeding up. The growth rate is 4.4 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 569.4 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.1bn.

Things to watch

  • Loss-making. Operating margin is -267.7%: costs exceed revenue.
  • Burning cash. Free cash flow was -271.6% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 52.7% of revenue, against a median of 19.2% for biotechnology companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 10.7% in a year.
  • High sales multiple. The shares trade at 17 times revenue while operating margins remain thin.
  • Volatile shares. Over the past year the shares showed annualised volatility of 72% and a beta of 2.2 against the S&P 500.

Latest results: FY2026 Q3

Filed November 3, 2026
Earnings per share
-$1.18 against an average estimate of -$1.13: missed by 4.8%
Revenue
$0m, down 96.8% on a year earlier
Next report
November 3, 2026; average EPS estimate -$1.17

Beam Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-5.0%
  • 1 week+8.7%
  • 1 month+5.6%
  • This year-6.7%
  • 1 year+3.4%
  • 5 years-72.7%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$147M
Operating margin
-267.7%
Net margin
-73.9%
EPS (TTM, diluted)
$-1.04

Growth

Revenue growth
+163.3%
Change in growth rate
+4.4 pts
Share count change
+10.7%

Cash

Free cash flow (TTM)
-$398M
FCF margin
-271.6%
Stock pay % of revenue
52.7%

Earnings

Last results
August 4, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Beam Therapeutics Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Beam Therapeutics Inc. as an operating company, with every model that fits that kind of business. Cost of equity 11.6%: the 10-year Treasury yield (4.9%) plus a beta of 1.47 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$8.1 ~$7.8–$8.3 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$1.9 ~$1.9–$7.2 Left out: out of range vs price (0.07x)
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$8.1 ~$7.8–$8.3 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Beam Therapeutics Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 202020212022202320242025Now
Share price$81.64$79.69$39.11$27.22$24.80$27.72$25.87
Market value$3.8bn$5.1bn$2.7bn$2.1bn$2.0bn$2.7bn$2.7bn
+ Net debt (− = net cash)−$162m−$560m−$233m−$436m−$282m−$295m−$113m
Enterprise value$3.7bn$4.6bn$2.5bn$1.7bn$1.8bn$2.4bn$2.6bn
Multiples
Price / sales n/m98.7x44.9x5.6x32.1x19.6x18.3x
Price / earnings ———————
Price / free cash flow ———————
EV / EBITDA ———————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

9 /100

Weak moat

How hard Beam Therapeutics's competitive advantage looks for rivals to wear away, judged from 7 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -24.3% of total assets over 7 years.

  • Durability 10 / 20

    Operating margin has been a median -488.4%; its worst year was -493050.0%.

  • Cash conversion 1 / 20

    Free cash flow was positive in 1 of 7 years, at a median -480.5% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 69.2% over five years; stock-based pay has been a median 120.8% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (14 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 3, 2026, before the open. Analysts expect revenue of $10m and EPS of −$1.17 (range −$1.28 to −$1.05) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$4.46 −450% $53m −62%
Next −$4.75 −7% $61m +15%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +0.5% on 90 days ago. In the last 30 days, 4 analysts raised Beam Therapeutics Inc.'s forecast and 5 cut it.

Consensus EPS forecast Beam Therapeutics Inc., last 90 days
−$6.00 −$4.00 −$2.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$4.43 Current fiscal year, 60 days ago: −$4.45 Current fiscal year, 30 days ago: −$4.45 Current fiscal year, 7 days ago: −$4.45 Current fiscal year, Now: −$4.46 −$4.46 Next fiscal year, 90 days ago: −$4.73 Next fiscal year, 60 days ago: −$4.74 Next fiscal year, 30 days ago: −$4.74 Next fiscal year, 7 days ago: −$4.74 Next fiscal year, Now: −$4.75 −$4.75

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$4.43−$4.73
60 days ago −$4.45−$4.74
30 days ago −$4.45−$4.74
7 days ago −$4.45−$4.74
Now −$4.46−$4.75

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$1.13 −$1.18 −4.8%
Mar 2026 −$1.01 −$0.91 +10.1%
Dec 2025 −$1.12 $2.33 +309.0%
Sept 2025 −$1.01 −$1.10 −8.9%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 4, 2026

No numeric guidance in Beam Therapeutics Inc.'s latest earnings release (filed August 4, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

15 analysts, Oct 2026
Buy1387%
Hold213%
Sell00%

Monthly trend

  1. Oct 202612215
  2. Sep 202612215
  3. Aug 202612215
  4. Jul 202612215

Counts of recommendations published by analysts covering Beam Therapeutics Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
39.3%
of tradable shares
Days to cover
13.87
at average volume
Short interest, 1 month
+1%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
1.2%
of shares
Employees
540
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +3.4%

$25.01 on October 31, 2025 to $25.87

ThenNowEffect
Revenue (last 12 months) $60m $156m +158.9%
P/S multiple 36.8x 17.1x −53.5%
Share count 89m 103m −14.0%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

Last 3 years +5.6%

$24.49 on November 3, 2023 to $25.87

ThenNowEffect
Revenue (last 12 months) $80m $156m +94.7%
P/S multiple 22.1x 17.1x −22.6%
Share count 72m 103m −29.9%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
BEAM−2%−51%−30%−9%+12%−7%
Industry peers (median)−36%−57%−17%−29%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
BEAM50%33%50%33%75%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
BEAM−49%−64%−64%−53%−57%−39%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since February 6, 2020: 89% from July 1, 2021 to April 8, 2025. Getting back needed a 819% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$20.60 – $37.92
From 52-week high
−31.8%
vs 50-day average
+0.1%
vs 200-day average
−8.0%
Volatility (1 year)
72%
Beta vs S&P 500
2.16

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±8.3%
After a week
4 up, 8 down
typical move ±8.5%
After a month
5 up, 7 down
typical move ±11.1%
Results releasedNext dayS&P 500 next day5 days21 days
August 4, 2026 +4.5% +1.6% +3.6% +13.0%
May 7, 2026 −0.1% +0.5% −8.7% −7.9%
February 24, 2026 +4.5% +1.6% −3.9% −18.4%
January 12, 2026 +25.4% 0.0% +12.4% −5.7%
November 4, 2025 −4.9% −0.8% −7.3% +19.2%
August 5, 2025 −4.3% +0.3% −11.8% −3.0%
May 6, 2025 −18.1% −0.4% −8.9% −14.2%
February 25, 2025 −9.4% −0.4% −14.1% −28.8%
January 13, 2025 −11.7% +0.3% −7.0% +8.3%
November 5, 2024 +9.3% +3.7% +14.7% +3.9%
August 6, 2024 −4.5% +0.2% −5.0% −5.6%
May 7, 2024 −2.4% +0.1% +4.5% +5.7%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Beam Therapeutics Inc. in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Beam Therapeutics Inc.
$0 $100M $200M $300M $400M FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $377.7M Revenue (TTM), FY24 Q1: $360.9M Revenue (TTM), FY24 Q2: $352.6M Revenue (TTM), FY24 Q3: $349.6M Revenue (TTM), FY24 Q4: $63.5M Revenue (TTM), FY25 Q1: $63.6M Revenue (TTM), FY25 Q2: $60.3M Revenue (TTM), FY25 Q3: $55.7M Revenue (TTM), FY25 Q4: $139.7M Revenue (TTM), FY26 Q1: $164M Revenue (TTM), FY26 Q2: $156M Revenue (TTM), FY26 Q3: $146.6M $146.6M

Source: SEC EDGAR filings. Retrieved November 3, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $377.7M
FY24 Q1 $360.9M
FY24 Q2 $352.6M
FY24 Q3 $349.6M
FY24 Q4 $63.5M
FY25 Q1 $63.6M
FY25 Q2 $60.3M
FY25 Q3 $55.7M
FY25 Q4 $139.7M
FY26 Q1 $164M
FY26 Q2 $156M
FY26 Q3 $146.6M
Revenue growth, TTM YoY Beam Therapeutics Inc.
-200% 0% 200% 400% 600% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue growth, TTM YoY, FY23 Q4: 520.0% Revenue growth, TTM YoY, FY24 Q1: 370.6% Revenue growth, TTM YoY, FY24 Q2: 339.8% Revenue growth, TTM YoY, FY24 Q3: 328.7% Revenue growth, TTM YoY, FY24 Q4: -83.2% Revenue growth, TTM YoY, FY25 Q1: -82.4% Revenue growth, TTM YoY, FY25 Q2: -82.9% Revenue growth, TTM YoY, FY25 Q3: -84.1% Revenue growth, TTM YoY, FY25 Q4: 120.0% Revenue growth, TTM YoY, FY26 Q1: 158.0% Revenue growth, TTM YoY, FY26 Q2: 158.9% Revenue growth, TTM YoY, FY26 Q3: 163.3% 163.3%

Source: SEC EDGAR filings. Retrieved November 3, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 520.0%
FY24 Q1 370.6%
FY24 Q2 339.8%
FY24 Q3 328.7%
FY24 Q4 -83.2%
FY25 Q1 -82.4%
FY25 Q2 -82.9%
FY25 Q3 -84.1%
FY25 Q4 120.0%
FY26 Q1 158.0%
FY26 Q2 158.9%
FY26 Q3 163.3%
Operating margin (TTM) Beam Therapeutics Inc.
-1000% -500% 0% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Operating margin (TTM), FY23 Q4: -46.7% Operating margin (TTM), FY24 Q1: -50.3% Operating margin (TTM), FY24 Q2: -52.3% Operating margin (TTM), FY24 Q3: -52.2% Operating margin (TTM), FY24 Q4: -654.3% Operating margin (TTM), FY25 Q1: -677.5% Operating margin (TTM), FY25 Q2: -739.9% Operating margin (TTM), FY25 Q3: -837.1% Operating margin (TTM), FY25 Q4: -274.6% Operating margin (TTM), FY26 Q1: -226.6% Operating margin (TTM), FY26 Q2: -242.3% Operating margin (TTM), FY26 Q3: -267.7% -267.7%

Source: SEC EDGAR filings. Retrieved November 3, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 -46.7%
FY24 Q1 -50.3%
FY24 Q2 -52.3%
FY24 Q3 -52.2%
FY24 Q4 -654.3%
FY25 Q1 -677.5%
FY25 Q2 -739.9%
FY25 Q3 -837.1%
FY25 Q4 -274.6%
FY26 Q1 -226.6%
FY26 Q2 -242.3%
FY26 Q3 -267.7%
FCF margin (TTM) Beam Therapeutics Inc.
-800% -600% -400% -200% 0% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: -48.4% FCF margin (TTM), FY24 Q1: -46.9% FCF margin (TTM), FY24 Q2: -43.5% FCF margin (TTM), FY24 Q3: -41.6% FCF margin (TTM), FY24 Q4: -560.8% FCF margin (TTM), FY25 Q1: -567.7% FCF margin (TTM), FY25 Q2: -589.9% FCF margin (TTM), FY25 Q3: -632.6% FCF margin (TTM), FY25 Q4: -257.7% FCF margin (TTM), FY26 Q1: -234.0% FCF margin (TTM), FY26 Q2: -238.9% FCF margin (TTM), FY26 Q3: -271.6% -271.6%

Source: SEC EDGAR filings. Retrieved November 3, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 -48.4%
FY24 Q1 -46.9%
FY24 Q2 -43.5%
FY24 Q3 -41.6%
FY24 Q4 -560.8%
FY25 Q1 -567.7%
FY25 Q2 -589.9%
FY25 Q3 -632.6%
FY25 Q4 -257.7%
FY26 Q1 -234.0%
FY26 Q2 -238.9%
FY26 Q3 -271.6%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Sept 2026
Income
Revenue 0 0 52 61 378 64 140 147
EBITDA −72 −128 −385 −324 −156 −394 −361 −370
Operating income −75 −133 −392 −338 −176 −416 −384 −393
Net income −78 −195 −371 −289 −133 −377 −80 −108
Diluted EPS −$14.05 −$4.19 −$5.77 −$4.13 −$1.72 −$4.58 −$0.81 −$1.04
Growth (year on year)
Revenue — +33.3% +>999% +17.5% +520.0% −83.2% +120.0% +163.3%
Margins
EBITDA margin <−999% <−999% −742.6% −532.4% −41.4% −619.7% −258.6% −252.6%
Operating margin <−999% <−999% −757.0% −555.6% −46.7% −654.3% −274.6% −267.7%
Net margin <−999% <−999% −714.9% −474.5% −35.1% −593.1% −57.2% −73.9%
Free-cash-flow margin <−999% <−999% −218.1% −43.4% −48.4% −560.8% −257.7% −271.6%
Cash flow
Cash from operations −72 −96 −66 23 −149 −347 −345 −389
Capital spending 13 16 47 49 34 9 15 10
Free cash flow −85 −112 −113 −26 −183 −356 −360 −398
Stock-based pay 7 15 44 84 99 121 94 77
Free cash flow after stock pay −92 −127 −157 −111 −282 −477 −454 −476
Balance sheet
Cash 37 162 560 233 436 282 295 213
Total debt 0 0 0 0 0 0 0 100
Net debt (negative = net cash) −37 −162 −560 −233 −436 −282 −295 −113
Diluted shares 6m 47m 64m 70m 77m 82m 99m 104m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

5 of 6 checks passed · September 30, 2026
What it owns · $1.3bn
Short-term assets $1.1bnLonger-term assets $202m
What it owes, and who funded it · $1.3bn
Short-term liabilities $82mLonger-term liabilities $234mShareholders' equity $953m
  • Short-term assets cover short-term liabilities $1.1bn of assets due within a year against $82m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $1.1bn short-term assets against $234m of longer-dated liabilities.
  • More cash than debt $213m of cash against $100m of debt.
  • Debt below 40% of shareholders' equity Debt is 11% of equity.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt −$389m of operating cash flow against $100m of debt.
  • Operating profit covers interest at least five times over No material interest expense reported.

From Beam Therapeutics Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+10.7%
year over year
R&D spending
278.9%
of revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated BEAM KPTI AGEN IBRX NUVB MESO Median
Revenue, last 12 months $147m $147m $133m $166m $170m $120m $56m
Revenue growth, last 12 months 163.3% 6.8% 30.5% 192.9% >999% 599.2% 12.8%
Revenue growth, 3-year average 21.6% 0.1% 10.1% 554.3% — — 13.7%
Revenue growth, latest quarter −96.8% −11.9% 34.4% 93.9% 555.6% — 10.2%
Gross margin — — 99.5% 99.3% 54.3% 86.1% 82.8%
Operating margin −267.7% −56.2% 27.3% −151.9% −81.0% — −189.4%
Operating margin, 3-year average −385.7% −76.7% −43.3% <−999% <−999% — −363.5%
Net margin −73.9% −153.3% 69.2% −598.6% −88.2% −47.8% −169.8%
Cash from operations / revenue −265.0% −44.6% −74.2% −169.6% −70.9% −36.4% −168.0%
Free-cash-flow margin −271.6% −44.6% −74.2% −173.8% −72.2% −37.1% −162.4%
Free-cash-flow margin, 3-year average −315.2% −69.7% −105.5% <−999% <−999% — −310.0%
Stock pay / revenue 52.7% 7.9% 8.0% 20.7% 20.9% 12.4% 20.0%
Change in share count 10.7% 22.0% 50.4% 26.1% 9.5% 7.2% 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth 163.3% 12.8% 28 of 172
Change in growth rate Growth +4.4pp -0.1pp 56 of 172
Operating margin Profitability -267.7% -189.4% 100 of 175
Net margin Profitability -73.9% -157.3% 72 of 180
Free-cash-flow margin Cash generation -271.6% -145.4% 110 of 176
Stock pay as % of revenue Cash generation 52.7% 19.2% 115 of 179
Long-term debt as % of assets Balance sheet 7.9% 20.6% 25 of 78
Change in share count Balance sheet 10.7% 7.9% 93 of 156

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$3.8B
Institutions reporting
275
Shares held vs prior quarter
▲ 1.0%
Positions opened / closed
55 / 30

Top buyers and sellers, Q2 2026: 148 institutions bought and 106 sold ; the biggest buyer was Morgan Stanley (+1.3M shares) and the biggest seller ARK Investment Management LLC (−1.9M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
FMR LLC $433M 12.6M 11.5% ▲ 1.3%
Farallon Capital Management, L.L.C. $351M 10.2M 9.4% ▲ 1.0%
ARK Investment Management LLC $351M 10.2M 9.4% ▼ 15.6%
Blackrock, Inc. $309M 9.0M 8.2% ▲ 6.0%
State Street Corp $200M 5.8M 5.3% ▲ 2.2%
Vanguard Portfolio Management LLC $169M 4.9M 4.5% ▲ 7.7%
Vanguard Capital Management LLC $158M 4.6M 4.2% ▲ 5.1%
Arch Venture Management, LLC $156M 4.5M 4.2% 0.0%
Sumitomo Mitsui Trust Group, Inc. $119M 3.5M 3.2% ▼ 9.7%
Amova Asset Management Americas, Inc. $119M 3.5M 3.2% ▼ 9.7%
Price T Rowe Associates Inc $117M 3.4M 3.1% ▲ 25.9%
Kynam Capital Management, LP $97.5M 2.8M 2.6% ▼ 22.9%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Beam Therapeutics Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $19.7M 31 trades by 7 insiders · 49% under pre-set plans
Net ▼ $19.7M net selling
Insider Date Trade Shares Price Value
Evans John M. CEO October 16, 2026 Sell pre-set plan 25,000 $23.98 $599,595
Evans John M. CEO October 15, 2026 Sell pre-set plan 25,000 $23.57 $589,150
Cavanagh Bethany J SVP, Finance and Treasurer October 1, 2026 Sell pre-set plan 187 $24.41 $4,565
Simon Amy Chief Medical Officer July 27, 2026 Sell pre-set plan 16,667 $25.74 $429,009
Evans John M. CEO June 30, 2026 Sell pre-set plan 1,900 $34.84 $66,196
Evans John M. CEO June 30, 2026 Sell pre-set plan 23,100 $34.26 $791,406
Simon Amy Chief Medical Officer June 30, 2026 Sell pre-set plan 373 $34.73 $12,954
Evans John M. CEO June 29, 2026 Sell pre-set plan 13,421 $35.13 $471,480
Evans John M. CEO June 29, 2026 Sell pre-set plan 11,579 $35.91 $415,802
Fmr Llc 10% owner June 26, 2026 Sell 251,488 $35.26 $8.9M
Fmr Llc 10% owner June 25, 2026 Sell 33,372 $35.12 $1.2M
Ciaramella Giuseppe President April 1, 2026 Sell pre-set plan 11,810 $24.58 $290,290

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around October 14, 2026 estimated from the company's past filing pattern, not announced

  • August 4, 2026
  • May 7, 2026
  • February 24, 2026
  • January 12, 2026
  • November 4, 2025
  • August 5, 2025

Recent SEC filings

Data status

When each part of this page on Beam Therapeutics Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Beam Therapeutics Inc. in brief

What does Beam Therapeutics Inc. do?
Beam Therapeutics Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Beam Therapeutics Inc.'s stock ticker?
Beam Therapeutics Inc. trades under the ticker BEAM on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Beam Therapeutics Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Beam Therapeutics Inc. reported revenue of $147M, 163.3% higher than a year earlier, according to its SEC filings.
What is Beam Therapeutics Inc.'s free cash flow?
Beam Therapeutics Inc.'s free-cash-flow margin is -271.6% of revenue over the trailing twelve months, ranking 110 of the 176 biotechnology companies we cover.
Who are Beam Therapeutics Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are FMR LLC, Farallon Capital Management, L.L.C. and ARK Investment Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Beam Therapeutics Inc.'s market cap?
On November 2, 2026, Beam Therapeutics Inc.'s market capitalisation was about $2.7B and net debt of -$113M. Market figures come from third-party market data and may be delayed.
How much debt does Beam Therapeutics Inc. have?
Beam Therapeutics Inc.'s debt-to-equity ratio is 10.5%, from its latest balance sheet. The financial health section below sets out its other solvency checks.
Who are Beam Therapeutics Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Beam Therapeutics Inc. are Karyopharm Therapeutics Inc., Agenus Inc, Immunitybio, Inc., Nuvation Bio Inc. and Mesoblast LTD. The side-by-side comparison below sets their revenue, margins and growth against Beam Therapeutics Inc.'s.
Are insiders buying or selling Beam Therapeutics Inc. stock?
Over the last 12 months, Beam Therapeutics Inc.'s directors and officers reported 0 open-market purchases and 31 sales on Form 4. The insider trading page charts every trade.
When is Beam Therapeutics Inc.'s next earnings date?
Around November 3, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Beam Therapeutics Inc. announces its own schedule.